Belvedere Trading’s Niagen Bioscience NAGE Stock Holding History

Belvedere Trading’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,700	Closed	-$63K	–	660
2021 Q3	$63K	Buy	+10,700	New	+$88.2K	﹤0.01%	401

Other funds holding NAGE

YRHAM

Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Belvedere Trading's NAGE Position: Q4 2021 in Review

Belvedere Trading sold out of Niagen Bioscience (NAGE) in Q4 2021, closing a stake of 5,960 shares — an estimated $35K sold.

Belvedere Trading first reported a position in NAGE in Q1 2021 and held it in 3 quarters. The position peaked at $412K in Q1 2021. 83 funds tracked by Wall St. Rank hold NAGE as of Q4 2021.

Belvedere Trading reported no remaining Niagen Bioscience position as of Q4 2021 after selling out during the quarter.
Belvedere Trading sold 5,960 Niagen Bioscience shares in Q4 2021, an estimated $35K.
Belvedere Trading first reported a position in Niagen Bioscience in Q1 2021 and held it in 3 quarters.
Belvedere Trading's Niagen Bioscience position peaked at $412K in Q1 2021.
83 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2021.

Based on Belvedere Trading's 13F filing for Q4 2021, filed 25 Jan 2022.